retatrutide cycle length First phase 3 data, a Triumph of Science! We are excited to announce

Vivid dreams are a commonly reported effect during Retatrutide treatment, likely related to metabolic changes and potential alterations in REM sleep patterns

The US Food & Drug Administration (FDA) removed tirzepatidethe active ingredient in the weight loss drug Zepbound from its shortage list last year

Current counts for 2026 fall within expected ranges, said the agency

As with other GLP-1 medicines, people with: A history of severe gastrointestinal disease Pancreatitis Significant kidney or liver issues should only use GLP-1 treatments under close clinical monitoring

Granhall C, Sndergaard FL, Thomsen M, Anderson TW